Rein Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Rein Therapeutics, Inc. (RNTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$29.37 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-30.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2020-03-30
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$7.03M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$7.43M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-06-30 was -$9.49M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$7.59M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$29.37M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$31.55M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2017 was -$22.64M.
- Rein Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2016 was -$18.20M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$29.37M 10-K · filed 2020-03-30 | |||
| 2018-12-31 | -$7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$14.47M derived: sum of 2 quarters · filed 2020-03-30 | -$23.96M derived: sum of 3 quarters · filed 2020-03-30 | -$31.55M 10-K · filed 2020-03-30 |
| 2018-09-30 | -$7.43M 10-Q · filed 2018-11-07 | -$16.93M derived: sum of 2 quarters · filed 2018-11-07 | -$24.51M 10-Q · filed 2018-11-07 | -$31.38M derived: sum of 4 quarters · filed 2019-03-29 |
| 2018-06-30 | -$9.49M 10-Q · filed 2018-08-07 | -$17.08M 10-Q · filed 2018-08-07 | -$23.94M derived: sum of 3 quarters · filed 2019-03-29 | -$30.20M derived: sum of 4 quarters · filed 2019-03-29 |
| 2018-03-31 | -$7.59M 10-Q · filed 2018-05-09 | -$14.45M derived: sum of 2 quarters · filed 2019-03-29 | -$20.71M derived: sum of 3 quarters · filed 2019-03-29 | -$25.66M derived: sum of 4 quarters · filed 2019-03-29 |
| 2017-12-31 | -$6.87M 10-K · filed 2019-03-29 | -$13.12M derived: sum of 2 quarters · filed 2019-03-29 | -$18.07M derived: sum of 3 quarters · filed 2019-03-29 | -$22.64M 10-K · filed 2019-03-29 |
| 2017-09-30 | -$6.26M 10-K · filed 2019-03-29 | -$11.20M derived: sum of 2 quarters · filed 2019-03-29 | -$15.78M 10-Q · filed 2018-11-07 | -$20.24M derived: sum of 4 quarters · filed 2019-03-29 |
| 2017-06-30 | -$4.94M 10-K · filed 2019-03-29 | -$9.52M 10-Q · filed 2018-08-07 | -$13.98M derived: sum of 3 quarters · filed 2019-03-29 | -$18.22M derived: sum of 4 quarters · filed 2019-03-29 |
| 2017-03-31 | -$4.58M 10-K · filed 2019-03-29 | -$9.04M derived: sum of 2 quarters · filed 2019-03-29 | -$13.28M derived: sum of 3 quarters · filed 2019-03-29 | -$18.83M derived: sum of 4 quarters · filed 2019-03-29 |
| 2016-12-31 | -$4.46M 10-K · filed 2018-04-02 | -$8.70M derived: sum of 2 quarters · filed 2018-04-02 | -$14.26M derived: sum of 3 quarters · filed 2018-04-02 | -$18.20M 10-K · filed 2018-04-02 |
| 2016-09-30 | -$4.24M 10-K · filed 2018-04-02 | -$9.79M derived: sum of 2 quarters · filed 2018-04-02 | -$13.74M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | -$5.55M 10-K · filed 2018-04-02 | -$9.50M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$3.94M 10-K · filed 2018-04-02 | |||
| 2015-12-31 | -$12.95M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |